Daniel M Altmann
Overview
Explore the profile of Daniel M Altmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
4023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Negash M, Girma T, Chanyalew M, H Alemayehu D, Alcantara D, Davey G, et al.
Trop Med Infect Dis
. 2024 Nov;
9(11).
PMID: 39591258
Epidemiological, histological, and immunogenetic studies suggest that podoconiosis (a non-infectious tropical lymphoedema affecting approximately 4 million people globally) is an HLA class II-associated inflammatory condition that develops in response to...
2.
3.
Negash M, Chanyalew M, Girma T, Alemu F, Alcantara D, Towler B, et al.
Nat Commun
. 2024 Mar;
15(1):2020.
PMID: 38448477
Available evidences suggest that podoconiosis is triggered by long term exposure of bare feet to volcanic red clay soil particles. Previous genome-wide studies in Ethiopia showed association between the HLA...
4.
Altmann D, Boyton R
Cell Host Microbe
. 2024 Feb;
32(2):147-148.
PMID: 38359794
The rapid evolution of COVID-19 Omicron variants is driven by evasion of neutralizing antibodies. Breakthrough infections are common, even in highly vaccinated populations, making it vital to understand immune cross-protective...
5.
Abhishek A, Peckham N, Pade C, Gibbons J, Cureton L, Francis A, et al.
Lancet Rheumatol
. 2024 Jan;
6(2):e92-e104.
PMID: 38267107
Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody...
6.
7.
Liu Z, Alexander J, Yee Eng K, Ibraheim H, Anandabaskaran S, Saifuddin A, et al.
J Crohns Colitis
. 2023 Nov;
18(4):560-569.
PMID: 37941436
Background And Aims: We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with inflammatory bowel disease [IBD]....
8.
Salgado B, Barbosa A, Arcanjo A, de Castro D, Ramos T, Naveca F, et al.
Viruses
. 2023 Oct;
15(10).
PMID: 37896766
We measured anti-SARS-CoV-2 antibody responses before and after CoronaVac (inactivated) vaccination in a case-control study performed in CoronaVac-immunized individuals participating in a longitudinal prospective study of adults in Manaus (DETECTCoV-19)....
9.
Liu Z, Alexander J, Le K, Zhou X, Ibraheim H, Anandabaskaran S, et al.
EClinicalMedicine
. 2023 Oct;
64:102249.
PMID: 37842172
Background: Patients with inflammatory bowel disease (IBD) receiving anti-TNF and JAK-inhibitor therapy have attenuated responses to COVID-19 vaccination. We aimed to determine how IBD treatments affect neutralising antibody responses against...
10.
Altmann D, Whettlock E, Liu S, Arachchillage D, Boyton R
Nat Rev Immunol
. 2023 Sep;
23(10):697.
PMID: 37723341
No abstract available.